Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

How Does Lunsumio Work for FL? Lunsumio is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Morningstar brands and products Company Portfolio ...

The FDA has granted a priority review to Roche's T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December. The first-in-class drug ...

Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, announced that it launched “Lunsumio for intravenous infusion 1 mg” and “Lunsumio for intravenous infusion 30 mg” (generic name: mosunetuzumab ...

Data showcase the benefits of fixed-duration Columvi (glofitamab-gxbm) and Lunsumio (mosunetuzumab-axgb) across different types of aggressive and indolent lymphomas. The company noted that long ...

Wednesday’s accelerated approval allows Epkinly to go toe to toe with Roche’s Lunsumio, which got its own third-line follicular lymphoma nod at the end of 2022. Both drugs are CD20xCD3 ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient ...

(2024-12-09 | OTCQX:RHHBY) New and Updated Data for Genentech's Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma Stockhouse.com ...